A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

Known as HKU5-CoV-2, the virus also appears capable of hooking onto other versions of ACE2 in multiple different mammals, ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that ...

Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

As COVID-19 surged across the US starting in 2020, so too did the use of repurposed medications such as hydroxychloroquine and ivermectin to treat COVID-19 infections. Use of these medications ...

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

为解决疫苗和抗病毒药物预防新冠重症及死亡的时变效应不明确问题，香港大学研究人员开展相关研究。结果发现两者保护效力随时间变化，接种多剂疫苗有效但第四剂后有衰减，口服抗病毒药 5 天内使用效果好。对优化抗疫策略意义重大，推荐阅读。

为解决新冠治疗药物的局限性问题，美国内布拉斯加大学医学中心的研究人员开展 9-AMN 靶向 SARS-CoV-2 PLpro 酶的研究。结果发现其能抑制病毒复制，与其他药物联用有协同效应。该研究为新冠治疗提供新思路，值得科研人员一读。

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...